112 related articles for article (PubMed ID: 19820363)
1. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer.
Nicoletto MO; Bertorelle R; Borgato L; De Salvo GL; Artioli G; Lombardi G; Zustovich F; Marcato R; Parenti A; Montagna M; Donach ME
Int J Gynecol Cancer; 2009 Aug; 19(6):1022-8. PubMed ID: 19820363
[TBL] [Abstract][Full Text] [Related]
2. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
[TBL] [Abstract][Full Text] [Related]
3. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
[TBL] [Abstract][Full Text] [Related]
4. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
5. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
[TBL] [Abstract][Full Text] [Related]
6. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
[TBL] [Abstract][Full Text] [Related]
7. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Kaye SB; Lubinski J; Matulonis U; Ang JE; Gourley C; Karlan BY; Amnon A; Bell-McGuinn KM; Chen LM; Friedlander M; Safra T; Vergote I; Wickens M; Lowe ES; Carmichael J; Kaufman B
J Clin Oncol; 2012 Feb; 30(4):372-9. PubMed ID: 22203755
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer.
Rapoport BL; Vorobiof DA; Slabber C; Alberts AS; Hlophe HS; Mohammed C
Int J Gynecol Cancer; 2009 Aug; 19(6):1137-41. PubMed ID: 19820382
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A; Vergote I; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Kaye SB; Colombo N; Lebedinsky C; Parekh T; Gómez J; Park YC; Alfaro V; Monk BJ
Ann Oncol; 2011 Jan; 22(1):39-48. PubMed ID: 20643862
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer.
Nicoletto MO; Falci C; Pianalto D; Artioli G; Azzoni P; De Masi G; Ferrazzi E; Perin A; Donach M; Zoli W
Gynecol Oncol; 2006 Feb; 100(2):318-23. PubMed ID: 16239023
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval.
Kaye SB; Colombo N; Monk BJ; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Vergote I; Lebedinsky C; Parekh T; Santabárbara P; Park YC; Nieto A; Poveda A
Ann Oncol; 2011 Jan; 22(1):49-58. PubMed ID: 20643863
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Kavanagh JJ; Levenback CF; Ramirez PT; Wolf JL; Moore CL; Jones MR; Meng L; Brown GL; Bast RC
J Hematol Oncol; 2010 Mar; 3():9. PubMed ID: 20222977
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
Marth C
Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.
Valerio MR; Tagliaferri P; Raspagliesi F; Fulfaro F; Badalamenti G; Arcara C; Cicero G; Russo A; Venuta S; Guarneri G; Gebbia N
Int J Gynecol Cancer; 2006; 16 Suppl 1():79-85. PubMed ID: 16515572
[TBL] [Abstract][Full Text] [Related]
15. Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.
Steffensen KD; Waldstrøm M; Pallisgård N; Lund B; Bergfeldt K; Wihl J; Keldsen N; Marth C; Vergote I; Jakobsen A
Int J Gynecol Cancer; 2013 Jan; 23(1):73-80. PubMed ID: 23211422
[TBL] [Abstract][Full Text] [Related]
16. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
[TBL] [Abstract][Full Text] [Related]
18. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.
Safra T; Rogowski O; Muggia FM
Int J Gynecol Cancer; 2014 Mar; 24(3):488-95. PubMed ID: 24457564
[TBL] [Abstract][Full Text] [Related]
19. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
20. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
